Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Preliminary results of phase Ib/II CAN-201 NDG trial.

Authors: Juan Manuel Sepulveda, Manuel Valiente, María Martínez-García, Estela Pineda, Maria Ángeles Vaz-Salgado, María Ruiz Vico, Gabriel Velilla, Manuel Mazariegos-Rubi, Izaskun Valduvieco, Maria Castro Henriques, Laia Cano, Stephen Garrett Marcus

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.2069

Source: Full article

---

Abstract

2069